title: Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer.
abstract: BACKGROUND
  Male breast cancer (MBC) is a rare malignant disease, accounting for <1% of all breast cancers (BCs). Treatment of men with early-stage BC is based on standards established in female BC. Prognostic or predictive markers to guide therapeutic decisions, in particular in early-stage male BC, are missing. Here, we explored whether disseminated tumor cells (DTC) in bone marrow (BM) and circulating tumor cells (CTC) in blood could be suitable biomarkers in male BC.
  
  
  METHODS
  Five male patients (pT2-4, pN0-2, M0) with hormone receptor-positive, HER2-negative, and ductal primary BC (median age 70 years, range 51-73) were enrolled in a prospective study of patients with early-stage breast cancer. Here, we analyze the male subgroup. DTC in BM were analyzed before therapy and identified by immunocytochemistry using the pancytokeratin antibody A45B/B3. Blood samples (10 ml) were analyzed for CTC using the AdnaTest BreastCancer (AdnaGen AG, Langenhagen, Germany).
  
  
  RESULTS
  DTC were found in three out of five male patients (60%) with two DTC detected in one patient and one DTC detected in each of the other two patients. This is compared to a detection rate of 25-40% in pooled analyses of female patients. CTC were only found in one of five patients. After a median follow-up time of 3 years (range 1-10 years), all patients were still alive and free of relapse.
  
  
  CONCLUSIONS
  The prevalence of DTC and CTC in male BC seems comparable with female BC. No prognostic relevance could be documented in this small population. A prospective study or at least larger cases series will be required to assess the prognostic or predictive value of DTC and CTC in this rare disease.
authors.affiliation: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany, mitra.tewes@uk-essen.de.
authors.forename: Mitra
authors.initials: M
authors.lastname: Tewes
authors.forename: Sabine
authors.initials: S
authors.lastname: Kasimir-Bauer
authors.forename: Anja
authors.initials: A
authors.lastname: Welt
authors.forename: Martin
authors.initials: M
authors.lastname: Schuler
authors.forename: Rainer
authors.initials: R
authors.lastname: Kimmig
authors.forename: Bahriye
authors.initials: B
authors.lastname: Aktas
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001853:Bone Marrow / Q000473:pathology*; D018567:Breast Neoplasms, Male / Q000097:blood / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000097:blood / Q000556:secondary*; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor
references.citation: J Clin Oncol. 2006 Aug 10;24(23):3756-62
references.pmid: 16769987
references.citation: Breast Cancer Res Treat. 2008 Dec;112(3):595-6
references.pmid: 18176840
references.citation: Gynecol Oncol. 2011 Aug;122(2):356-60
references.pmid: 21605893
references.citation: Ann Surg Oncol. 1997 Jul-Aug;4(5):385-8
references.pmid: 9259964
references.citation: Br J Cancer. 2006 Mar 13;94(5):672-80
references.pmid: 16495933
references.citation: Anticancer Res. 2005 May-Jun;25(3A):1803-10
references.pmid: 16033103
references.citation: N Engl J Med. 2005 Aug 25;353(8):793-802
references.pmid: 16120859
references.citation: J Clin Oncol. 2002 Aug 15;20(16):3404-12
references.pmid: 12177100
references.citation: Breast Cancer Res. 2009;11(4):R59
references.pmid: 19664291
references.citation: Am J Clin Pathol. 2004 May;121(5):631-6
references.pmid: 15151202
references.citation: Eur J Cancer. 2008 Dec;44(18):2726-36
references.pmid: 19056036
references.citation: Cancer Biol Ther. 2011 Sep 1;12(5):379-82
references.pmid: 21725206
references.citation: Ann Surg Oncol. 2009 Apr;16(4):972-8
references.pmid: 19184227
references.citation: J Clin Oncol. 2010 Jan 10;28(2):232-9
references.pmid: 19996029
references.citation: J Exp Clin Cancer Res. 2004 Sep;23(3):465-8
references.pmid: 15595637
references.citation: Clin Cancer Res. 2005 Feb 1;11(3):1154-9
references.pmid: 15709183
references.citation: Anticancer Res. 2011 Oct;31(10):3623-8
references.pmid: 21965788
references.citation: BMC Cancer. 2013 Oct 15;13:480
references.pmid: 24128322
references.citation: Ann Oncol. 2012 Sep;23(9):2271-2277
references.pmid: 22383680
references.citation: Int J Cancer. 2006 Apr 15;118(8):2013-9
references.pmid: 16287086
references.citation: J Clin Oncol. 2009 May 1;27(13):2177-84
references.pmid: 19332733
references.citation: Breast Cancer Res Treat. 2006 May;97(1):91-6
references.pmid: 16319975
references.citation: Clin Cancer Res. 2005 May 15;11(10):3678-85
references.pmid: 15897564
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Cytotherapy. 1999;1(5):377-88
references.pmid: 20426539
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8152-62
references.pmid: 15623589
references.citation: Clin Cancer Res. 2011 May 01;17(9):2967-76
references.pmid: 21415211
references.citation: Breast Cancer Res. 2012 Aug 14;14(4):R117
references.pmid: 22889108
references.citation: Cancer. 2006 Sep 1;107(5):885-92
references.pmid: 16874814
references.citation: J Natl Cancer Inst. 1998 Jul 15;90(14):1099-101
references.pmid: 9672259
references.citation: Cancer. 1998 Aug 1;83(3):498-509
references.pmid: 9690543
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5342-8
references.pmid: 15328170
references.citation: Eur J Cancer. 1994;30A(7):930-5
references.pmid: 7946586
references.citation: Mol Biotechnol. 2006 Sep;34(1):15-27
references.pmid: 16943567
references.citation: Clin Breast Cancer. 2013 Oct;13(5):309-14
references.pmid: 23845572
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5615-21
references.pmid: 17020963
references.citation: Breast Cancer Res. 2009;11(4):R46
references.pmid: 19589136
references.citation: Anticancer Res. 2007 May-Jun;27(3A):1337-41
references.pmid: 17593628
references.citation: Ann Oncol. 2013 Jun;24(6):1434-43
references.pmid: 23425944
references.citation: Breast Cancer Res. 2012 Jan 20;14(1):R15
references.pmid: 22264265
references.citation: Clin Cancer Res. 2004 Feb 15;10(4):1392-400
references.pmid: 14977842
references.citation: Eur J Cancer. 2011 Jul;47(10):1527-36
references.pmid: 21334874
references.citation: Dtsch Med Wochenschr. 2008 Feb;133(7):285-9
references.pmid: 18253918